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ABSTRACT
Small RNAs targeted to gene promoters in human
cells can mediate transcriptional gene silencing
(TGS) by directing silent state epigenetic modifica-
tions to targeted loci. Many mechanistic details
of this process remain poorly defined, and the abil-
ity to stably modulate gene expression in this
manner has not been explored. Here we describe
the mechanisms of establishment and maintenance
of long-term transcriptional silencing of the
human ubiquitin C gene (UbC). Sustained targeting
of the UbC promoter with a small RNA for a min-
imum of 3 days resulted in long-term silencing
which correlated with an early increase in histone
methylation and a later increase in DNA methylation
at the targeted locus. Transcriptional silencing of
UbC required the presence of a promoter-asso-
ciated RNA. The establishment and maintenance of
the TGS were shown to require distinct protein fac-
tors. Argonaute 1 (Ago1), DNA methyltransferase 3a
(DNMT3a) and histone deacetylase 1 (HDAC1) were
required for the initiation of silencing, and DNA
methyltransferase 1 (DNMT1) was necessary for
maintenance. Taken together the data presented
here highlight the cellular pathway with which non-
coding RNAs interact to epigenetically regulate
gene expression in human cells.
INTRODUCTION
The study of gene regulation has greatly expanded over
the past several years as numerous RNA-mediated reg-
ulatory mechanisms have been discovered (1). One such
method is termed RNA-mediated transcriptional gene
silencing (TGS), by which promoter-targeted small
RNAs can, in some cases, induce transcriptional silencing
in a homology-dependent manner. As the body of
literature on this subject grows and more genes are
shown to be susceptible to this form of transcriptional
regulation, a putative model of this mechanism in
human cells has begun to take shape. In this model, the
generation and activity of small RNA molecules requires
Argonaute 1 (Ago1) (2,3). Target recognition occurs as
the antisense strand of the promoter-targeted small
RNA binds to a complementary promoter-associated
RNA (pRNA) (4,5). Interestingly, several recent reports
have shown that transcription of promoter regions is
much more common that previously realized (6–8).
Upon exposure to the small RNA, the targeted promoter
exhibits higher levels of the silent state histone
methyl marks H3 lysine-9 di-methylation (H3K9me2)
and histone H3 lysine-27 tri-methylation (H3K27me3)
(2,4,9,10). These silent state chromatin marks have been
observed not only at the targeted locus, but also
downstream, 30 of the target site, providing a possible
mechanism by which silent state histone methyl marks
may extend to aﬀect neighboring genes or intergenic
regions (10,11). A role for DNA methylation in this pro-
cess remains uncertain, as some targeted promoters
have been observed to exhibit increased CpG methylation
(12), while others have not (13).
Protein factors responsible for these enzymatic pro-
cesses constitute a partially characterized transcriptional
silencing complex (TSC). Recent work indicates that this
putative TSC may contain DNMT3a (10), Ago-1 (2,9),
HDAC-1 (14) and histone methyltransferases such as
enhancer of zeste homolog 2 (Ezh2) and/or G9a (4,15).
In some instances Argonaute 2 (Ago2) has been shown
to be required for TGS (9), and recently published work
indicates that the varying incorporation of Ago1 and
Ago2 may depend on the level of complementarity
between the small RNA and its target (16).
Recently, several labs have begun to identify and
describe endogenous examples of RNA-mediated TGS in
human cells. One ﬁnding in this area is the discovery that
RNA-mediated TGS appears to play an important role in
early transcriptional silencing events which lead to human
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reports have identiﬁed the ﬁrst examples of endogenously
expressed promoter targeted miRNAs which mediate TGS
(16,18). It has also been shown that some noncoding, anti-
sense transcripts may direct TGS to their respective sense
promoters to possibly aﬀect the local chromatin signature
(19, 20), and that targeting these antisense transcripts can
lead to activation of sense transcription (21,22). Recent
genome-wide studies indicate that nonrandom antisense
transcription is widespread in the human genome, and
may represent a prevalent mechanism of transcriptional
regulation (23).
While much is known regarding the temporal aspects
of targeting coding regions with siRNAs and miRNAs
in a post-transcriptional manner (PTGS), far less is
known regarding the ability of small RNA molecules to
direct long-term gene silencing. Additionally, speciﬁc
cellular proteins which could mediate such a process
remain uncharacterized. To address these questions we
studied transcriptional gene silencing of the human
ubiquitin C gene (UbC). Ubiquitin is directly involved
in skeletal muscle atrophy, which is a serious complication
of catabolic conditions (24), as well as Parkinson’s disease
(25) and space travel (26). Additionally, much is known
about the transcriptional features of Ubiquitin, making
it an ideal gene for further study (27).
MATERIALS AND METHODS
UbC dsRNAs transfections and mRNA knockdown
Two dsRNAs were generated to determine the target
susceptibility of the UbC gene promoter and screened
in 293Gt GripTight
TM, Ntera and 2102Ep cells (Invit-
rogen). 1.0 10
5cells were transfected in quadruplicate
(100nM, Lipofectamine
TM 2000 and/or RNAiMAX
TM,
Invitrogen). Forty-eight hours later the cultures were col-
lected, mRNA isolated (CellsDirect
TM Invitrogen) and
UbC expression determined relative to GAPDH expres-
sion by quantitative real-time PCR (qRT-PCR) with
UbC mRNAF and UbC mRNAR, and GAPDHF and
GAPDHR primers (Table S1) as described in ref. (4).
TSA treatment
Roughly 5  10
5 293Trex-UBC167 cells were transfected in
triplicate with pENTER
TM/H1/TO-167 or pENTER
TM/
H1/TO-308 plasmids, containing an shRNA targeted to
the 167 and 308 target sites of UbC cloned into the
BlockIT system (Invitrogen
TM)( 1 mg/1 10
6cells), or
UBC167 or UBC308 dsRNAs, targeted to the 167 and
308 sites, respectively (100nM, Lipofectamine 2000
TM).
Cultures were treated with or without 0.05mM TSA.
ShRNA samples were treated with or without Tet, and
additional samples were transfected with a CCR5-targeted
siRNA as a control for the dsRNA samples. Culture
mRNA was isolated (Qiagen, RNeasy
TM) 48h later. The
resulting RNA was then DNase treated (Turbo DNA
Free, Ambion
TM), reverse transcribed (Superscript III,
Invitrogen
TM) and analyzed by qPCR (Sybr Green
Invitrogen
TM) using GAPDH and the UbC mRNA-speciﬁc
primers UBIC Fwd and Rev (Table S1). The qPCR results
were standardized ﬁrst to GAPDH, and subsequently
to untreated control values.
Nuclear run-on
Cell cultures,  1.0   10
6 293GT, were transfected with
either the UBC167 dsRNA or the CCR5 siRNA (control)
siRNAs (100nM, Lipofectamine 2000
TM). Nuclear run-on
was performed as described in (28) although subsequent
analysis was slightly modiﬁed to use biotin tagged tran-
scripts (29). Biotinlyated RNA was pulled down using
Dynabeads (Invitrogen
TM), after which cDNA copies of
pulled down RNA were generated (Superscript III,
Invitrogen
TM). QPCR was then performed using
GAPDH and UBIC primers (Table S1). A dot blot
of pulled down RNA was also performed using
GAPDH and UBIC Rev primers and the Ambion
BrightStar detection system per manufacturer’s guidelines.
ChIP assay
Roughly 4 10
6 HEK 293GT cells (Invitrogen) plate were
transfected in replicate with either UBC167, UBC308, or
CCR5 (Control) (28) dsRNAs (100nM, Lipofectamine
2000
TM) (Table S1). In the case of the ODN blocking
ChIP assays, the cultures (4.0 10
6/10cm plate) were
ﬁrst transfected with the respective antisense ODNs
(100nM, Lipofectamine 2000
TM) followed 4h later by a
transfection with the UBC167 dsRNA (100nM,
Lipofectamine 2000
TM). In the case of Figure 2D,
293Trex-UBC167 cells were treated with or without Tet
for 7 days. Next, the cultures were collected and a ChIP
assay performed as described in ref. (4). Antibodies used:
anti-dimethyl-H3K9 (Upstate #07-441), anti-trimethyl-
H3K27 (Upstate #07-449), anti-Ago1 (Upstate #07-599),
anti-acetyl-Histone H3K14 (Upstate #07-353), anti-NF-
kB (Zymed, #51-0500), anti-RNAPII CTD (AbCam
#ab817) and anti-RNAPII phosphor-S2 (AbCam
#ab5095). Immunopreciptated DNA was then recovered
by phenol/chloroform extraction and assayed by qPCR
using indicated primers overlapping the promoter (1 and
2), farther downstream (4 and 5) and upstream of the
target site (7 and 8) (Table S1) (Sybr Green
TM,
Invitrogen).
UbCpromoter RNA detection
To determine the expression of the UbC promoter-
associated RNA by RT-PCR, total 293Gt cellular
mRNA was DNase treated (Turbo DNA Free,
Ambion
TM) and reverse transcribed (Superscript III,
Invitrogen
TM). CDNA samples were then PCR
ampliﬁed (Platinum PCR Supermix, Invitrogen
TM) with
primers 1 and 2 (Table S1) and analyzed on a 6% polya-
crylamide gel.
ODNblocking experiments
To determine the role of promoter-associated RNAs
in small RNA-mediated TGS of the UbC gene, phosphor-
othioate oligodeoxynucleotides (ODNs) (30) were gener-
ated (IDT, Coralville, Iowa) to target the UBC167
target site (Table S1). Next, 293GT cells (5.5 10
5/well
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6/10cm plate for RT PCR and ChIP assays
respectively) were plated and 24h later transfected with
the respective ODNs (100nM (30), Lipofectamine
2000
TM). Four hours later the ODN transfected cultures
were transfected with the UbC targeted dsRNAs (100nM,
Lipofectamine 2000
TM). Forty-eight hours following
the dsRNA transfection the dually transfected cultures
were collected and cellular RNA isolated, converted to
cDNA and used in qRT-PCR for UbC mRNA expression
with the UbC mRNA-speciﬁc UBICFwd and UBICRev
primers (Table S1) (described above).
Analysisof promoter-associated RNA levelsupon
UBC167targeting
Six samples of  1 10
6 293Trex cells were transfected
with pENTER
TM/H1/TO-167 plasmid, containing an
shRNA targeted to the 167 target site of UbC cloned
into the BlockIT system (Invitrogen
TM)( 1 mg/1 10
6
cells, Lipofectamine 2000
TM). Triplicate samples were
treated with or without Tet for 48h. RNA was
isolated (Rneasy
TM, Qiagen), DNase treated (Turbo
DNA Free, Ambion
TM) and reverse transribed (Super-
script III, Invitrogen
TM). Samples were then pooled,
ampliﬁed (Platinum PCR Supermix, Invitrogen
TM) with
primers 1 and 2 (Table S1), and analyzed by 6% polya-
crylamide electrophoresis, or analyzed by qPCR using
primers 1 and 2 (Table S1) (Sybr Green Mastermix
Invitrogen
TM).
Time-course expression assays
Roughly 5 10
5 293Trex-UBC167 cells were treated with
or without 1mg/ml Tet for the amount of time indicated.
RNA was isolated, DNAse treated, converted to cDNA
and analyzed by qRT-PCR with the UBIC and GAPDH
primers (Table S1) (described above).
Quantification of UBC167shRNA expression in
stablecells
Small RNAs were collected (miRVana
TM, Ambion)
on Days 0, 7 and 12 from time-course experiment (see
above) and DNase treated (Turbo DNA free
TM,
Ambion). Poly(A) tails were added to samples
(NCode
TM, Invitrogen
TM), which were analyzed by
qPCR using universal qPCR primer (NCode
TM,
Invitrogen) and 167S/AS primer (Table S1).
Suppression of Ago1,DNMT3a, HDAC1, Ezh2 and G9a
293Trex-UBC167 Tet-inducible BlockIt cells were
generated (according to manufacture’s instructions,
Invitrogen
TM). Roughly 5 10
5 293Trex-UBC167 cells
were transfected with siRNAs targeting Ago-1,
DNMT3a, HDAC-1, Ezh2 or G9a in triplicate, and
treated with 1mg/ml Tet daily. For controls, CCR5 was
used. Culture mRNA was isolated (Quiagen, RNeasy
TM)
72h after transfection. The resulting mRNAs were then
DNase treated (Turbo DNA Free, Ambion
TM), converted
to cDNA (Superscript III, Invitrogen
TM) and analyzed by
Sybr Green qPCR using GAPDH and UBIC primers
(Table S1). The qPCR results were standardized ﬁrst
to GAPDH, and subsequently to control values. The
same isolated RNA samples were also analyzed by
qPCR with target gene primers (Table S1) to conﬁrm
suppression, and results were standardized ﬁrst to
GAPDH, and then to control samples.
Reactivation of UbCexpression
Roughly 4 10
6 293Trex-UBC167 cells were treated with
1mg/ml Tet for 7 days. Tet was removed from the samples
whichwereculturedforanadditional5days.The cellswere
then split into ﬁve separate plates of roughly 4 10
5cells
each. These samples were then transfected with siRNAs
targeting CCR5 (control), Ago1, HDAC1, DNMT3a,
DNTM1 at 100nM, or DNTM3a and DNTM1 at 50nM
each (Lipofectamine 2000
TM). Additional samples were
treated with 50AzaC (4mM). Forty-eight hours later cellu-
lar RNA was isolated from these samples (Rneasy
TM,
Qiagen), DNase treated (Ambion turbo DNA free),
copied to cDNA (Superscript III, Invitrogen
TM), and
analyzed by qPCR using UBIC and GAPDH primer sets
(Table S1) (Sybr Green Mastermix Invitrogen
TM). The
same isolated RNA samples were also analyzed by qPCR
with target gene primers (Table S1) to conﬁrm suppression,
and results were standardized ﬁrst to GAPDH, and then to
control samples.
DNA methylation-specific digestion
293Trex-UBC167 cells were treated with Tet for 10 days.
Duplicate samples of  5 10
5cells were isolated prior to
Tet treatment and after indicated days of treatment. DNA
was extracted (Dneasy
TM, Qiagen), pooled and digested
with the methylation-sensitive enzymes HhaI and HpaII
(NEB), the methylation-dependent enzyme McrBC
(NEB), or both. RT-PCR was performed on samples
using primers speciﬁc for the UbC promoter region
(1 and 2) (Table S1). RT-PCR was optimized to account
for presence of enzyme buﬀer using the Epicentre real
time PCR optimization kit. The proportions of densely,
intermediately and unmethylated DNA were calculated
using the method described by Ordway et al. (31,32).
DNA methylation-specific PCR
DNA samples isolated by trimethyl-H3K27 pull down
from the ChIP in Figure S3 were bisulﬁte treated
(Zymo-ResearchTM). After conversion, methylation-
dependent and methylation-sensitive PCRs were per-
formed using the respective UbC target site primers
(Table S1). PCR products were analyzed on a 6% poly-
acrylamide gel.
RESULTS
Susceptibility of human UbCto promoter targeting
To determine the susceptibility of human UbC to RNA-
mediated TGS, we transiently transfected promoter-
targeted duplex RNAs spanning various regions of the
UbC promoter (27,33) (Figure 1A), and monitored UbC
expression in three diﬀerent cell types by qRT-PCR. UbC
expression was signiﬁcantly reduced in all cell types
2986 Nucleic Acids Research, 2009, Vol. 37,No. 9targeted with the UBC308 duplex RNA. In contrast,
variation in target susceptibility at the UBC167 locus
was observed in a cell-line-speciﬁc manner (Figure S1).
To conﬁrm the results of the initial screen regarding
the UbC167 duplex RNA in 293Gt cells, and to address
the eﬃcacy and speciﬁcity of the silencing activity of the
UBC167 dsRNA, we compared its silencing activity
with those of a scrambled UBC167 RNA duplex and a
PTGS inducing, mRNA targeting stealth RNA. As mea-
sured by qRT-PCR, knock down achieved using the
UBC167 duplex RNA was comparable to that achieved
by mRNA targeting, and the scrambled UBC167 RNA
did not induce silencing of UbC (Figure 1B).
Previously, we and others have observed that RNA
directed TGS in human cells is operative via directed
epigenetic modiﬁcations at the targeted promoter
(2,10,13,28,34). In order to diﬀerentiate between TGS
and other types of gene silencing, and to determine if
chromatin modiﬁcations were necessary for the observed
silencing, we assessed the sensitivity of the silencing
induced by UBC167 and UBC308 dsRNAs to the histone
deacetylase inhibitor trichostatin A (TSA). In 293Gt
cells, gene suppression achieved upon targeting the 167
site was sensitive to TSA treatment, while targeting the
308 site was not (Figure 1C). These data were recapitu-
lated in an almost identical experiment in which we
Figure 1. Transcriptional silencing of UbC.( A) The UbC promoter and exon 1 are shown schematically with the target sites UBC167 and UBC308,
TATAA signal, transcriptional start site, and primary qPCR primers. (B) Promoter targeting with dsRNA is eﬀective and speciﬁc. 293Gt cells
were transfected with either an siRNA targeting the UbC coding region (Stealth UBC), a scrambled UBC167 promoter-targeted dsRNA
(UBC167 scramble), or the original UBC167 dsRNA, and samples were analyzed by qRT-PCR for UbC mRNA levels 48h later. Results were
standardized to GAPDH levels, and quadruplicate treated cultures were assessed with the standard errors of the means shown. (C) UbC suppression
by 167 targeting synthetic duplex RNAs is sensitive to TSA, while 308 targeting is not. 293Gt cells were transfected with CCR5 (control), UBC167 or
UBC308 dsRNAs in triplicate. Twenty-four hours later cultures were treated with TSA (0.05mM). Forty-eight hours following TSA treatment
the cultures were assessed for UbC expression standardized to GAPDH. Average values from triplicate transfected cultures with standard errors of
the means are shown. (D) UbC suppression by a Tet-inducible UBC167 shRNA is sensitive to TSA treatment, while silencing by a similar UBC308
shRNA is not. 293Trex cells were transfected with either UBC167 or UBC308 expressing Tet-inducible plasmids, and treated with or without Tet.
Twenty-four hours later these cultures were treated with TSA (0.05mM). Forty-eight hours following TSA treatment the cultures were assessed
for UbC mRNA levels standardized to GAPDH. Average values with standard errors of the means are shown.
Nucleic Acids Research,2009, Vol.37, No. 9 2987transiently transfected plasmids containing tetracycline
(Tet)-inducible 167 and 308 shRNA constructs
(Figure 1D). These results indicate that while UBC167
targeting may induce TGS, targeting the 308 site (which
overlaps the TATA box and transcriptional start site)
may cause silencing by a separate mechanism, such as
post-transcriptional gene silencing.
Mechanism ofUBC167-mediated silencing
To more clearly establish that the observed silencing
of UbC was indeed occurring at the transcriptional
level, nuclear run-on was performed on 293Gt cultures
transfected with CCR5 (control) or UBC167 dsRNAs.
Nuclear run-on samples were analyzed using a novel
biotin pulldown-based assay previously described by
Zhang and colleagues (29) in addition to a standard
dot blot. In cells transfected with the UBC167 duplex
RNA, transcription was signiﬁcantly reduced in compar-
ison with control samples, indicating that the observed
silencing was occurring at the transcriptional level
(Figure 2A).
To more clearly deﬁne the mechanism of this gene
silencing, we performed chromatin immunoprecipitation
assays (ChIP) with antibodies directed against histone
H3K9me2, H3K27me3 and Ago-1. Compared to CCR5
siRNA-treated control samples, a signiﬁcant enrichment
of H3K9me2, H3K27me3 and Ago-1 were observed at the
promoter upon targeting with the UBC167 duplex RNA
(Figure 2B). Interestingly, similar enrichments were also
observed at the promoter after treatment with the
UBC308 small RNA (Figure 2C), despite the earlier
observation that histone methylation is not required for
the silencing activity of UBC308. These data do not
necessarily contradict the results from Figure 1B and C
which showed that silencing mediated by ds308 is not
aﬀected by TSA treatment. This result may indicate that
small RNAs targeted to various gene sequences, including
mRNA targeting si- and miRNAs, may direct epigenetic
changes to corresponding DNA loci, even if their mode
of silencing does not require such modiﬁcations.
Previous reports have shown that silent state chromatin
marks, speciﬁcally H3K9me2, can be found 30 of the
targeted promoter region (2,10). Consistent with these
reports, we show that treatment of cells with either
UBC167 or UBC308 small RNAs resulted in enhanced
levels of H3K9me2, H3K27me3 and Ago-1 recruitment
30 of the small RNA targeted loci (Figure 2B and C).
Interestingly, we were unable to detect a noticeable enrich-
ment of either H3K27me3 or Ago-1 when upstream
sites were assessed by ChIP (Figure S2).
An additional ChIP assay was performed using anti-
bodies against the activating mark AcH3K14, NF-kB
and RNA polymerase II. For this ChIP, and subsequent
long-term experiments discussed below, we developed a
novel 293-Trex cell line which contains a tetracycline-
inducible UBC167 shRNA construct (293Trex-UBC167
cells). Treating these cells with tetracycline (Tet) leads
to expression of the 167 shRNA. Targeting the UbC
promoter in this manner resulted in a loss of activating
factors such as NF-kB and AcH3K14, with no decrease
in overall levels of RNAPII at the targeted locus
(Figure 2D). Interestingly, the retained RNAPII, found
speciﬁcally at the small RNA target locus, was predom-
inantly the inactive form of RNAPII (Figure S3).
Collectively, these data show that the UbC promoter
transitions from an active state towards a silent state
when targeted with synthetic duplex or shRNAs.
This demonstrated mechanism is similar to previously
reported examples of small RNA-directed TGS in
human cells (35).
A promoter-associated RNA is requiredfor TGS
Recent work from our laboratory has shown that a
sense-stranded promoter-associated RNA is required for
RNA-directed transcriptional gene silencing in human
cells (4). To determine the extent of transcription across
the UbC promoter, speciﬁcally at the UBC167-targeted
locus, we performed RT-PCR with primers speciﬁc
for this region. Similar to previous observations (4), a
promoter-associated transcript was observed overlapping
the UBC167-targeted region in the UbC promoter
(Figure 3A). Previous observations have also shown that
suppression of promoter-associated RNAs results in the
abrogation of TGS (4). To ascertain whether a UbC pro-
moter-associated RNA is required for TGS of UbC,a
blocking experiment was performed. To block the UbC
promoter-associated RNA, phosphorothioate oligodeoxy-
nucleotides (ODN) (30) were designed to recognize
the cognate promoter-associated RNA for either the
UBC167 sense or antisense directional transcript.
Phosphorothioate ODNs hybridize to complementary
genetic regions and induce RNA cleavage at the hetero-
duplex by activation of the RNase H pathway (36).
Results of treatment with the sense and antisense ODNs
indicated that the promoter-associated RNA is sense-
oriented, as the UbC antisense ODN was eﬀective in
reducing the promoter-associated RNA expression
(Figure 3B). To determine the ability of the UBC167
dsRNA to modulate TGS in the absence of the UbC
promoter-associated RNA, cells were treated with either
the sense- or antisense-targeted ODN, and then four hours
later with the UbC targeting dsRNAs. Blocking of the
UbC promoter-associated RNA by ODN treatment
resulted in a loss of UBC167-directed TGS (Figure 3C).
We next investigated the abundance of the promoter-
associated RNA upon targeting the UBC167 site. This
was done by performing RT-PCR and qRT-PCR on
RNA isolated from samples which we transiently trans-
fected with plasmids containing a Tet-inducible 167
shRNA construct in the presence and absence of Tet.
These results show that promoter-associated RNA levels
are decreased but not completely suppressed (Figure 3D).
This decrease in promoter-associated RNA levels may be
the result of a blockage of RNAPII transcription by the
assembled TSC, which transcription most likely originates
from an upstream location.
To determine the requirement of the promoter-
associated RNA for the induction of epigenetic
modiﬁcations at the targeted UbC promoter, we sup-
pressed the UbC promoter-associated RNA by ODN
2988 Nucleic Acids Research, 2009, Vol. 37,No. 9treatment, and then analyzed the epigenetic marks
at the targeted locus by ChIP assay. The suppression
of the UbC promoter-associated RNA expression by
antisense ODN treatment resulted in a reduction
of RNA-directed H3K9me2 and H3K27me3 at the
UBC167 targeted locus compared to sense ODN
treated controls (Figure 3E). Furthermore, there were no
observable changes in H3K9me2 and H3K27me3
enrichment upstream of the targeted locus (Figure S4).
Taken together, these data recapitulate previous obser-
vations (4), and suggest that a promoter-associated
RNA is necessary for promoter-targeted small RNAs
to direct silent state epigenetic modiﬁcations to gene
promoters.
Figure 2. Mechanism of UBC167 induced silencing. (A) UBC167-mediated suppression of UbC expression in 293Gt cells is operative via transcrip-
tional gene silencing. Nuclear run-on assay was carried out on UBC167 or Control (CCR5) duplex RNA treated cultures 48h post-transfection.
Run-on RNA samples containing incorporated biotin UTP were immunopreciptated and analyzed by dot blot and qRT-PCR (29). (B, C) UBC167
and UBC308 direct silent state histone marks H3K9me2 and H3K27me3, and Ago-1 to the targeted locus. UBC167, UBC308 or CCR5 (control)
dsRNA-treated 293Gt cells were assessed by ChIP for H3K9me2, H3K27me3 and Ago-1 at various regions of the UbC gene. Cultures were assessed
48h post-dsRNA transfection with primers spanning the target site and downstream of the known TATAA site. Standard errors of the means are
shown from quadruplicate duplex RNA treated cultures. (D) Activating chromatin marks are lost following UBC167 treatment, while RNAPII
remains. ChIP analysis was performed using antibodies against NF-kB (p65), AcH3K14 and RNAPII, followed by PCR and qPCR with UbC
promoter-speciﬁc primers. Samples were isolated from stable Tet-inducible 293Trex-UBC167 cells treated with Tet for 3 days.
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The observation that epigenetic modiﬁcations such as
histone methylation occur at the UbC promoter upon
small RNA treatment suggests that long-term gene silenc-
ing can be induced. To determine the eﬀects of persistent
targeting of the UBC167 site on chromatin composition
and gene expression, we again used our UBC167 shRNA
Tet-inducible cell line. The maintenance of long-term
suppression of UbC, following a 7-day induction,
could be observed for over a month (Figure 4A).
Importantly, signiﬁcant increases in UBC167 shRNA
were detectable after 7 days of sustained Tet treatment,
but were found to return to pre-induction levels of detec-
tion 5 days later, after removal of Tet (Figure 4B), indi-
cating that a signiﬁcant increase in shRNA expression
is required to establish but not maintain the observed
silencing. Upon further investigation, approximately 3
days of sustained shRNA exposure was required in divid-
ing cells (Figure 4C), and only 2 days of shRNA exposure
in serum starved nondividing cells (Figure 4D) to establish
Figure 3. The requirement of the UbC promoter-associated RNA in TGS. (A) Detection of a promoter-associated RNA spanning the UbC promoter
by RT-PCR of total RNA from 293Gt cells, using primers speciﬁcally spanning the UBC167 targeted locus. (B) Antisense ODN treatment results in
loss of UbC promoter-associated RNA. 293Gt cells were left untreated (mock), transfected with UBC167-speciﬁc ODNs, either sense (Sense ODN) or
antisense (Antisense ODN), and promoter-associated RNA expression determined by RT-PCR 48h later. (C) Antisense ODN suppresses small
RNA-mediated TGS. 293Gt cells were transfected with either UBC167 sense or antisense ODNs in quadruplicate followed 4h later by transfection
with UBC167 dsRNA. Forty-eight hours later the samples were collected and analyzed by qRT-PCR to assess aﬀect of ODN treatment on TGS.
Results were standardized to GAPDH expression, and triplicate treated cultures were assessed with the standard errors of the means shown. The
respective P-values for paired T-tests from each treatment relative to the control are also shown. (D) Promoter-associated RNA levels are modestly
decreased upon targeting. 293Trex cells were transfected with a Tet-inducible 167 shRNA plasmid and treated with or without Tet in triplicate. RNA
was isolated from these samples 48h later and converted to cDNA. These cDNA samples were then pooled, ampliﬁed by PCR and analyzed on a 6%
polyacrylamide gel, or analyzed independently by qRT-PCR using UbC promoter primers 1 and 2. The standard errors of the mean from three
independent samples are shown. (E) Suppression of UbC promoter-associated RNA inhibits UBC167-mediated histone methylation. 293Gt cells were
transfected with UBC167-speciﬁc ODNs, either sense or antisense, followed 4h later by transfection with UBC167 dsRNA. Forty-eight hours later a
ChIP assay was performed for H3K9me2 or H3K27me3 with primers speciﬁc for the UBC167 target site. Quadruplicate treated cultures were
assessed and the standard errors of the means are shown along with P values for paired T-tests from each treatment relative to the control.
2990 Nucleic Acids Research, 2009, Vol. 37,No. 9long-term silencing of UbC. These data suggest that long-
term silencing of gene expression can be achieved when
promoter regions are targeted with small RNAs for a
relatively short period of time. It was also noted that
upon long-term down-regulation of UbC, cell-growth
rates slowed and adherence was weakened. These observa-
tions can most likely be attributed to the signiﬁcant,
sustained down-regulation of a necessary cellular protein.
Establishment and maintenanceof TGS require
distinct subsetsof protein factors
The observation that silent state histone methyl marks
correlate with the observed small RNA-mediated tran-
scriptional silencing of UbC implicates a central role of
various epigenetic factors in this process. To ﬁrst deter-
mine the involvement of several such factors in the estab-
lishment of transcriptional silencing of UbC, we used
RNAi to knockdown these targets in the context
of our Tet-inducible cell line, and assessed the eﬀects of
each knockdown on TGS after 72h. Knockdown of each
targeted gene was conﬁrmed by qRT-PCR (Figure S5).
Establishment of transcriptional silencing of UbC in this
context required the activities of DNMT3a, Ago-1,
HDAC1 and to some extent G9a, but not EZH2
(Figure 5A).
We next used a similar approach to determine necessary
factors for the maintenance of TGS. We again used RNAi
to knockdown several targets in our Tet-inducible cell line.
The indicated targets were knocked down after 12 days,
7 days of Tet-induction followed by 5 days removed from
Tet. Forty-eight hours after siRNA transfection, UbC
transcript levels were determined by qRT-PCR. We
show that in this system, maintenance of TGS required
DNMT1, but not Ago1 or HDAC1, and that UbC expres-
sion was also rescued by treatment with 50AzaC
(Figure 5B). A role for DNMT3a in the maintenance of
gene silencing is not completely apparent from these
results. While the statistical signiﬁcance of the DNMT3a
data is not particularly clear, modest increases in UbC
expression in siDNTM3a, and siDNTM3a and
siDNMT1-treated samples over control and siDNMT1
Figure 4. Long-term gene silencing of UbC.( A) Long-term gene silencing. 293Trex-UBC167 cells were treated with Tet for 7 days, and then removed
from Tet for 24 more days. Cellular mRNA was isolated from the treated cultures and UbC expression assessed at indicated times by qRT-PCR
and standardized to GAPDH. The averages are shown with standard errors of the means. (B) UBC167 shRNA expression following 7 days of
sustained Tet treatment. 293Trex-UBC167 cells were treated with Tet for 7 days, and then removed from Tet for ﬁve more. Small RNAs were
isolated, polyadenlyated, converted to cDNA and analyzed by RT-PCR performed using primers speciﬁc for the UBC167 shRNA. The lower panel
depicts the quantitative expression of UBC167 shRNA as determined by qPCR. (C) A minimum of 3 days of sustained UBC167 shRNA expression
is required to establish long-term silencing. 293Trex-UBC167 cells were treated with Tet for either 1, 2, 3 or 4 days consecutively, and then cultured
for another 7 days in the absence of Tet. UbC mRNA expression was determined after 7 days in the absence of Tet and standardized to GAPDH
expression. (D) A minimum of 2 days of sustained UBC167 shRNA expression is required to establish long-term silencing under serum starved
conditions. 293Trex-UBC167 cells were serum starved for 48h and then treated with Tet for either 1, 2 or 3 days consecutively, and then cultured
for another 7 days in the absence of Tet. UbC mRNA expression was determined after 7 days in the absence of Tet and standardized to GAPDH
expression.
Nucleic Acids Research,2009, Vol.37, No. 9 2991Figure 5. Characterization of protein factors necessary for establishment and maintenance of TGS. (A) Deﬁning components involved in the
induction of small RNA-mediated TGS of UbC. 293Trex-UBC167 cells were transfected with various siRNAs targeted to CCR5 (Control), G9a,
HDAC-1, DNMT3a, Ago-1 or Ezh2 and then treated with Tet for 3 days to induce UBC167 shRNA expression. On Day 3, cellular mRNA was
isolated and UbC expression determined relative to GAPDH. The averages for three independent samples and the respective standard errors of the
means are shown along with P-values for paired T-tests from each treatment relative to the control. (B) Deﬁning components involved in maintaining
small RNA-mediated TGS of UbC. 293Trex-UBC167 cells were treated with Tet for 7 days to induce UBC167 shRNA expression and establish long-
term silencing. Samples were then removed from Tet. Five days after the removal from Tet the cultures were transfected with siRNAs targeted to
CCR5 (Control), Ago-1, HDAC-1, DNMT3a, DNMT1 or DNTM3a and DNTM1, or treated with 50AzaC. Forty-eight hours later the cellular
mRNA was isolated and analyzed by qRT-PCR to determine UbC expression relative to GAPDH. The averages for three independent samples and
the standard errors of the means are shown along with P-values for paired T-tests from each treatment relative to the control.
2992 Nucleic Acids Research, 2009, Vol. 37,No. 9samples respectively may indicate that DNMT3a might
play a role in maintaining transcriptional silencing.
Role ofDNA methylation in long-term TGS
Another epigenetic mark frequently found in stably
silenced genes is DNA methylation (38). To assess the
methylation state of the UbC promoter upon small RNA
targeting, we ﬁrst compared methyl-speciﬁc digestion pro-
ﬁles of cells cultured with and without Tet over 10 days.
Interestingly, DNA methylation was shown to increase
upon prolonged treatment with Tet, as calculated
using the method of methylation-speciﬁc restriction
digest analysis described in refs (31,32,39) (Figure 6A).
Notably, the increase in DNA methylation required several
days, and correlated with a time when robust long-term
gene silencing had already been established (Figure 6B),
suggesting that DNA methylation functions primarily
in maintaining long-term silencing of UbC.
To further investigate the methylation state of the
targeted promoter we then used methyl-speciﬁc PCR.
Both an enrichment of methylated DNA and a decrease
of unmethylated DNA were detectable at the targeted
promoter in H3K27me3 immunopreciptated DNA (from
the experiment shown in ﬁgure S3) (Figure 6C).
DISCUSSION
The data presented here demonstrate that targeting
promoters with small noncoding RNAs can induce long-
term transcriptional gene silencing in human cells. We also
show distinct mechanisms for the establishment and
maintenance of this gene silencing. Similar to previous
ﬁndings, the induction of the observed gene silencing
was operative via site-speciﬁc histone methylation, which
required the presence of a UbC promoter-associated RNA
(4), HDAC-1 (14), DNMT3a (10) and Ago-1 (2). The
observation that knockdown of Ezh2 results in an only
moderate inhibition of the induction of TGS might indi-
cate that H3K27me3 is not required for the silencing, but
acts in an additive manner, or that various histone methy-
lation enzymes are functional in a redundant manner.
Maintenance of UbC silencing required a distinct subset
of proteins, namely DNMT1 and possibly DNMT3a. This
observation is particularly interesting as a synergistic
interaction between DNMT1 and DNMT3a has also
been observed in CpG methylation of LINE elements
(40). In addition, signiﬁcant DNA methylation was
detected after several days of sustained small RNA target-
ing, at a time when robust histone methylation of the
targeted locus had already taken place. This delay in the
occurrence of DNA methylation may in part explain why
DNA methylation has not been observed in all instances
of RNA-mediated TGS (11).
It is noted that cells transfected with UBC308-targeted
RNA were not sensitive to TSA treatment. Future
experiments are aimed at determining whether sequence-
speciﬁc gene silencing may be operative via additional
mechanisms, such as obstructing the activity of RNAPII
at the transcriptional start site (41). Such a hypothesis
could in part explain why targeting the 308 site was
not cell-line-speciﬁc, while targeting of the 167 site was.
This might be understood by noting that targeting the
167 site is dependent on TGS, which requires cell-speciﬁc
factors such as a promoter-associated RNA and the
activity of various proteins. It is important to note,
however, that while UBC308 targeting was not observed
Figure 6. Role of DNA methylation in long-term transcriptional silen-
cing. (A) Increased DNA methylation at the UbC promoter was observed
several days post Tet induction of UBC167 shRNA. Genomic DNA was
collected and pooled from duplicate samples of 293Trex-UBC167 cells
treated without Tet (Day 0) and after 1, 2, 3 or 10 days of Tet treatment.
Proportion of densely, intermediately and unmethylated DNA was cal-
culated using method described (31). Methyl-sensitive restriction
enzymes: HpaII and HhaI, methyl-dependent restriction enzyme:
McrBC. qPCR was performed using promoter-speciﬁc primers. (B)
Silencing of UbC is observed after Tet treatment. 293Trex-UBC167
cells were treated with Tet for 10 days. Cellular mRNA was isolated at
various time points and UbC expression relative to GAPDH determined.
The averages with the standard errors of the means are shown as deter-
mined by qRT-PCR along with P-values for paired T-tests from each
treatment relative to the control. (C) DNA from H3K27me3 ChIP
(Figureure S3) was treated with bisulﬁte and analyzed by methylation-
speciﬁc PCR using primers speciﬁc for methylated or unmethylated DNA
species overlapping the UBC167 target site.
Nucleic Acids Research,2009, Vol.37, No. 9 2993to induce TGS of UbC, chromatin modiﬁcations were
nevertheless observed upon targeting. This may indicate
that small RNAs can induce chromatin remodeling
events, even if their primary mode of action is not at the
transcriptional level, which may represent a novel mode
of oﬀ-target eﬀect which may result from classical RNAi
experiments.
Overall, the data presented here provide the ﬁrst evi-
dence that promoter targeted small RNAs can induce
long-term TGS in human cells. In addition, the mecha-
nisms of induction and maintenance of this TGS are char-
acterized and shown to be distinct. These results may be
indicative of the ability of endogenous mechanisms, such
as noncoding RNAs (42), to regulate transcription in a
long-term manner, and may also prove a useful avenue
for future gene therapy applications.
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